001     911484
005     20230123101839.0
037 _ _ |a FZJ-2022-04753
100 1 _ |a Drzezga, Alexander
|0 P:(DE-Juel1)177611
|b 0
|u fzj
245 _ _ |a PET and SPECT Imaging of Neurodegenerative Diseases
260 _ _ |a Amsterdam
|c 2021
|b Elsevier
295 1 0 |a Molecular Imaging: Principles and Practice
300 _ _ |a 1309-1334
336 7 _ |a BOOK_CHAPTER
|2 ORCID
336 7 _ |a Book Section
|0 7
|2 EndNote
336 7 _ |a bookPart
|2 DRIVER
336 7 _ |a INBOOK
|2 BibTeX
336 7 _ |a Output Types/Book chapter
|2 DataCite
336 7 _ |a Contribution to a book
|b contb
|m contb
|0 PUB:(DE-HGF)7
|s 1668669151_29672
|2 PUB:(DE-HGF)
500 _ _ |a
520 _ _ |a Today, a number of complementary molecular imaging methods are at our disposal, which can make a relevant contribution to early diagnosis, differential diagnosis, disease monitoring, and follow-up of neurodegenerative diseases. This includes long-established FDG-PET which provides valuable information on location and extent of pathology and has demonstrated great value for early diagnosis, short-term prognosis, and for differential diagnosis of various disorders on the basis of the endophenotype of disease. Imaging of the dopaminergic system has proven value in the workup of movement disorders. More recently introduced, amyloid-PET for the first time allows in vivo diagnostic assessment of a molecular neuropathology, most valuable for verification or exclusion of Alzheimer disease (AD), independent of the symptomatic appearance. Finally, new tracers for tau-PET imaging may allow the assessment of location, extent, and specific type of pathology, which may hold great value for early and differential diagnosis of neurodegeneration in the future.
536 _ _ |a 5252 - Brain Dysfunction and Plasticity (POF4-525)
|0 G:(DE-HGF)POF4-5252
|c POF4-525
|f POF IV
|x 0
536 _ _ |a 5253 - Neuroimaging (POF4-525)
|0 G:(DE-HGF)POF4-5253
|c POF4-525
|f POF IV
|x 1
700 1 _ |a Bischof, Gérard
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Giehl, Kathrin
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Eimeren, Thilo van
|0 P:(DE-HGF)0
|b 3
856 4 _ |u https://www.researchgate.net/publication/354825733_PET_and_SPECT_Imaging_of_Neurodegenerative_Diseases
909 C O |o oai:juser.fz-juelich.de:911484
|p VDB
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)177611
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5252
|x 0
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5253
|x 1
914 1 _ |y 2022
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-2-20090406
|k INM-2
|l Molekulare Organisation des Gehirns
|x 0
980 _ _ |a contb
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-2-20090406
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21